A physicist who investigates the ­properties of organic molecules discusses his work--and his surprising career in musical theater.

As a PhD candidate in chemistry at Harvard’s Graduate School of Arts and Sciences (GSAS) Kerr is working on an alternative battery technology—redox flow—that makes use of pumped liquid electrolytes to store energy.

Malinda McPherson, PhD '22, is changing the way that scientists understand how people hear—and how culture shapes the experience of music.

PhD candidate Ju Chulakadabba on MethaneSAT —a project that uses satellite technology to measure and locate methane emissions from oil and gas operations around the world—and how the data it generates will allow countries to identify, manage, and ultimately reduce their greenhouse gas emissions, a critical goal in the fight against global warming.

Larissa Zhou envisions a future where people don’t just survive in space, they thrive—with hot delicious food to sustain them. As a PhD candidate in materials science and mechanical engineering at Harvard’s Graduate School of Arts and Sciences (GSAS...

Nabiha Saklayen, PhD '17, hopes to combine laser physics, optical imaging, machine learning, robotics, and biology to dramatically lower the cost of stem cell therapies—and bring them to scale.

Astrophysicist Brian Schmidt, PhD '93, on winning the 2011 Nobel prize and how he brings the skills of a scientist to the leadership of one of Australia’s top academic institutions.

What does it mean to be a human in a world that's dominated by science and technology—and in a universe in which we might not be alone? With the advancement of observational technology—for instance, the new James Webb...

In this episode of the Harvard Horizons podcast, PhD student Nicolò Foppiani asks whether the "sterile neutrino" exists and whether it could explain one of the greatest mysteries in astrophysics: the source of dark matter.

In this Harvard Horizons presentation, Harvard University PhD student Harry Won describes a new approach to treating tuberculosis: by targeting and destroying critical parts of TB’s cellular “machine.”